Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma



Status:Archived
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Phase II, Open Label, Single Center Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma


This study is designed to explore the molecular modulatory effect of Sunitinib when given in
a neoadjuvant setting prior to radical or partial nephrectomy. The study will evaluate
aforementioned outcomes in 30 patients at a dose of 50mg/day for 4 weeks followed by surgery
2-4 weeks following the last dose.



We found this trial at
1
site
David Geffen School of Medicine, UCLA
10833 Le Conte Ave
Los Angeles, California 90095
(310) 825-4321
David Geffen School of Medicine, UCLA In 2002 Mr. David Geffen announced a $200 million...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials